A Phase Ib, Multi-center, Open-label, Dose-escalation Study of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 Administered Orally in Patients With Myelofibrosis
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2018
At a glance
- Drugs PIM 447 (Primary) ; Ribociclib; Ruxolitinib
- Indications Myelofibrosis
- Focus Adverse reactions
- Sponsors Novartis
- 21 Feb 2018 Planned End Date changed from 26 Jul 2018 to 31 Dec 2018.
- 21 Feb 2018 Planned primary completion date changed from 29 Dec 2017 to 31 Dec 2018.
- 21 Feb 2018 Status changed from recruiting to active, no longer recruiting.